RGN-259
What the Research Actually Shows
Human: 3 studies, 1 groups · Animal: 0 · In Vitro: 0
The thymosin β4 eye drop that healed 60% of neurotrophic keratopathy patients in Phase III—a fundamentally different approach to corneal regeneration than nerve growth factor, and potentially a broader one
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
RGN-259 is an eye drop made from thymosin β4, a small protein your body uses to help cells move and heal. In a Phase III trial for neurotrophic keratopathy—a condition where corneal nerves die and the surface breaks down—60% of patients on RGN-259 healed completely, compared to 12.5% on placebo. None of the healed patients relapsed. Two Phase II trials in dry eye disease also showed significant improvements in both symptoms and corneal health. RGN-259 works differently from cenegermin (the approved NGF treatment for NK)—instead of regrowing nerves, it directly tells surface cells to migrate and close the wound. The results are encouraging, but the Phase III NK trial was small (18 patients), and no FDA approval has been granted yet.
The cornea has a problem that two different peptides are trying to solve from opposite directions. Cenegermin—already FDA-approved—approaches corneal healing through the nervous system: replace the missing nerve growth factor, regrow the nerves, and the surface heals because the neurotrophic support is restored. RGN-259 approaches the same problem through the cytoskeleton: deliver thymosin β4, the protein that tells epithelial cells how to reorganize their internal scaffolding and migrate across a wound, and the surface heals because the cells physically move to close the defect.
The distinction matters. Not every corneal wound is caused by nerve damage, and not every patient responds to neural trophism restoration. RGN-259's mechanism—cell migration, anti-inflammation, anti-apoptosis—is relevant to any condition where the corneal surface needs to heal, regardless of nerve status. That makes its potential therapeutic scope broader than cenegermin's, even if its regulatory path is behind.
The clinical data supports the promise. A Phase III trial in neurotrophic keratopathy showed 60% complete healing versus 12.5% on placebo. Two Phase II dry eye trials showed significant improvement in both signs and symptoms. The question is no longer whether thymosin β4 works in the eye. The question is whether GtreeBNT (the company behind RGN-259) can translate positive trial results into regulatory approval and market access.
In This Article
Quick Facts: RGN-259 at a Glance
Type
Regenerative peptide — 43-amino acid naturally occurring protein, formulated as 0.1% ophthalmic solution
Also Known As
Thymosin β4 ophthalmic solution, Tβ4 eye drops, thymosin beta-4
Generic Name
Thymosin β4 (recombinant)
Brand Name
None (investigational — no trade name assigned)
Molecular Weight
~4,963 Da
Peptide Sequence
43-amino acid peptide; full sequence: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Endogenous Origin
Produced by virtually every nucleated cell in the body; the most abundant actin-sequestering peptide in mammalian cells. Originally isolated from thymus tissue.
Primary Molecular Function
G-actin monomer sequestration → cytoskeletal remodeling → epithelial cell migration + anti-inflammatory (reduces IL-1β, TNF-α, NF-κB) + anti-apoptotic → corneal wound healing
Active Fragment
Full-length 43-amino acid thymosin β4 (the complete peptide is the active form, not a fragment)
Related Compound Relationship
Competes with cenegermin (NGF) for NK treatment but uses a fundamentally different mechanism. Also related to systemic thymosin β4 studied for cardiac repair—RGN-259 is the topical ocular formulation.
Clinical Programs
Phase III neurotrophic keratopathy (completed, positive). Phase II dry eye ARISE-1 and ARISE-2 (completed, positive). Developer: GtreeBNT (formerly RegeneRx Biopharmaceuticals).
Key Clinical Findings
Phase III NK: 60% (6/10) complete healing vs. 12.5% (1/8) placebo at 4 weeks, zero recurrences. ARISE-1 (N=72): significant corneal staining and symptom improvement. ARISE-2 (N=48): 27% discomfort reduction vs. placebo.
Route
Topical ophthalmic drops (0.1% solution, 1 mg/mL)
WADA Status
Not on Prohibited Lists
FDA Status
NOT approved. Phase III complete for NK. Phase II complete for dry eye. Regulatory path ongoing.
Biggest Evidence Gap
Phase III NK trial enrolled only 18 patients. FDA typically requires larger pivotal studies. No Phase III dry eye data yet.
Evidence Tier
2 Clinical Trials
Verdict
Reasonable Bet
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is RGN-259?
Pronunciation: are-jee-en two-five-nine
Your body heals a cut on your skin by mobilizing cells to migrate across the wound and close the gap. The protein that orchestrates much of that migration—the one that reorganizes the cell's internal scaffolding so it can move in the right direction—is thymosin β4. It is the single most abundant actin-sequestering peptide in every nucleated cell you have. When a cell needs to move, thymosin β4 releases actin monomers from storage, allowing the cytoskeleton to polymerize in the direction of travel. Without it, cells sit still. With it, they march.
RGN-259 is a 0.1% ophthalmic solution of synthetic thymosin β4, developed to deliver this migration signal directly to the corneal surface. The cornea is an ideal target: it is one of the most rapidly renewing tissues in the body, healing depends almost entirely on epithelial cell migration from the periphery to the center, and topical delivery gives direct drug access without systemic exposure.
The compound emerged from RegeneRx Biopharmaceuticals (now GtreeBNT), a company that has been developing thymosin β4 for wound healing applications since the early 2000s. The ocular formulation was a strategic bet: the eye is a contained system with objective healing endpoints (you can photograph the cornea and measure defect size precisely), making clinical trials cleaner and faster than dermal wound healing studies.
PLAIN ENGLISH
RGN-259 is an eye drop containing a natural protein called thymosin β4 that helps cells move and heal. Every cell in your body uses this protein to reorganize its internal structure when it needs to migrate—like the way skin cells crawl across a cut to close it. RGN-259 delivers a concentrated dose of this protein directly to the corneal surface, telling the cells to move faster and close the wound.
Origins and Discovery
Thymosin β4 was first isolated from calf thymus in 1981 by Allan Goldstein and colleagues at George Washington University. The name is a historical artifact—despite being called a "thymosin," thymosin β4 is not thymus-specific and has nothing to do with thymic immune function. It is a ubiquitous cytoskeletal protein that was simply first purified from thymic tissue.
The wound-healing connection came in the late 1990s, when researchers demonstrated that exogenous thymosin β4 accelerated dermal wound closure in animal models. The corneal application followed logically: Gabriel Sosne at Wayne State University showed that topical thymosin β4 promoted corneal epithelial migration and reduced inflammation in animal models of corneal injury. RegeneRx Biopharmaceuticals licensed the technology and developed RGN-259 as a clinical-grade ophthalmic formulation.
The journey from academic discovery to Phase III trial took roughly two decades—a timeline that reflects both the genuine difficulty of ophthalmic drug development and the financial constraints of a small biotech company pursuing a biological product. The acquisition by GtreeBNT injected new capital and regulatory momentum.
PLAIN ENGLISH
Thymosin β4 was discovered in 1981 from calf thymus glands—but despite the name, it has nothing to do with the immune system. It's actually a universal cell-movement protein. Researchers found it could speed up wound healing in the late 1990s, and a scientist at Wayne State University showed it worked on the cornea. A company turned it into clinical-grade eye drops, and it's been in human trials since the 2010s.
Mechanism of Action
RGN-259's therapeutic effect in the cornea emerges from at least five converging mechanisms, all downstream of thymosin β4's interaction with the actin cytoskeleton and inflammatory signaling pathways.
Actin Sequestration and Cell Migration
Thymosin β4's primary molecular function is binding G-actin monomers—the building blocks of the actin filaments that form a cell's internal skeleton. By sequestering these monomers, Tβ4 maintains a reservoir of unpolymerized actin. When a wound creates a migration signal, Tβ4 releases actin monomers on demand, enabling rapid filament assembly at the leading edge of migrating epithelial cells. This is not a generic growth signal—it is a specific mechanical instruction that tells cells to reorganize their cytoskeleton and move directionally toward the wound.
In the cornea, this mechanism is directly therapeutic. Persistent epithelial defects—the hallmark of neurotrophic keratopathy—fail to heal precisely because epithelial cells cannot migrate across the exposed stroma. RGN-259 provides the migration signal that the damaged tissue cannot generate on its own.
Anti-inflammatory Pathway Modulation
Corneal wounds that fail to heal are typically sustained by a self-perpetuating inflammatory cycle: tissue damage releases pro-inflammatory cytokines (IL-1β, TNF-α), inflammation damages more tissue, and the cycle continues. Thymosin β4 interrupts this cycle by suppressing NF-κB signaling—the master transcription factor for inflammatory gene expression. In the Phase II dry eye trials, reduced corneal staining (a marker of surface inflammation) correlated with symptom improvement, consistent with anti-inflammatory activity.
Anti-apoptotic Protection
At wound margins, stressed epithelial cells undergo apoptosis, expanding the defect even as migration attempts to close it. Thymosin β4 has demonstrated anti-apoptotic properties in corneal models, protecting cells at the wound edge and preserving the cellular population available for wound closure.
Limbal Stem Cell Mobilization
The corneal epithelium regenerates from limbal stem cells housed at the peripheral corneal-scleral junction. Animal studies suggest thymosin β4 promotes limbal stem cell activation and migration centrally. If confirmed in humans, this mechanism would make RGN-259 fundamentally regenerative—restoring the corneal surface from its stem cell source rather than just promoting existing cell migration.
Matrix Metalloproteinase Regulation
In advanced corneal disease, uncontrolled MMP activity degrades the stromal matrix, leading to corneal melting and perforation. Thymosin β4 modulates MMP expression, potentially preventing the destructive remodeling that makes some corneal defects progress from surface damage to structural compromise.
PLAIN ENGLISH
RGN-259 works through five pathways at once: (1) it gives corneal cells the building materials they need to move and close a wound; (2) it calms the inflammation that keeps wounds from healing; (3) it protects cells at the wound edge from dying; (4) it may activate the stem cells that regenerate the entire corneal surface; and (5) it prevents enzymes from dissolving the corneal structure underneath. Unlike NGF (cenegermin), which works by regrowing nerves, RGN-259 works by directly telling surface cells to migrate—a fundamentally different approach.
Key Research Areas and Studies
Neurotrophic Keratopathy — Phase III
The pivotal Phase III trial (Sosne et al., 2023, PMID 36613994) was a randomized, placebo-controlled, double-masked study in 18 patients with neurotrophic keratopathy (NK). Patients received RGN-259 0.1% eye drops four times daily for four weeks. The results were striking: 60% of RGN-259-treated patients (6 of 10) achieved complete corneal healing at four weeks, compared to 12.5% (1 of 8) on placebo. At day 43, no RGN-259-healed patient had recurred, while the single placebo-healed patient did experience recurrence.
The effect size is large and clinically meaningful. But the sample size—18 patients—is small by Phase III standards. FDA approval pathways for rare diseases can accommodate smaller trials, and NK qualifies as rare (~5 per 10,000), but the small N introduces statistical uncertainty. Whether this trial alone is sufficient for regulatory submission, or whether a confirmatory study will be required, depends on the regulatory strategy GtreeBNT pursues.
Dry Eye Disease — ARISE-1
The ARISE-1 trial (Sosne et al., 2015, PMID 25826322) was a randomized Phase II study in 72 patients with severe dry eye disease. Patients received RGN-259 0.1% eye drops six times daily for 28 days. Compared to placebo, RGN-259 produced significant improvements in corneal fluorescein staining (an objective measure of surface damage), discomfort scores, and tear breakup time (a measure of tear film stability).
Dry Eye Disease — ARISE-2
The ARISE-2 trial (Sosne et al., 2015, PMID 26056426) used a controlled adverse environment (CAE) model—an artificial chamber that exacerbates dry eye symptoms—to test RGN-259 in 48 patients. Discomfort scores were reduced by 27% compared to placebo (p=0.0244). Significant improvements in central and superior corneal staining were also observed.
The CAE model is valuable because it standardizes the environmental challenge, reducing variability. The consistent results across ARISE-1 (natural environment) and ARISE-2 (controlled environment) strengthen the dry eye signal.
PLAIN ENGLISH
Three clinical trials tell a consistent story. In neurotrophic keratopathy, RGN-259 healed 60% of patients versus 12.5% on placebo—though only 18 patients were studied. In dry eye, two separate trials (72 patients and 48 patients) both showed the drops improved symptoms and reduced corneal damage. The results are positive across all three studies, but the numbers are still relatively small.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"RGN-259 heals neurotrophic keratopathy"” | Phase III RCT (N=18): 60% vs. 12.5% complete healing at 4 weeks. Strong effect size, small sample. | Supported |
| “"RGN-259 is better than cenegermin for NK"” | No head-to-head comparison exists. Cross-study comparison: cenegermin 69.6% (N=48) vs. RGN-259 60% (N=10). Different mechanisms, different trial designs. | Unsupported |
| “"RGN-259 cures dry eye disease"” | Two Phase II trials showed significant improvements in signs and symptoms. No Phase III data. Dry eye is chronic—28-day studies don't establish long-term cure. | Mixed Evidence |
| “"Thymosin β4 regenerates the cornea from stem cells"” | Animal studies suggest limbal stem cell mobilization. No human data confirms this mechanism. | Preclinical Only |
| “"RGN-259 is safer than cenegermin"” | Both compounds show similar mild adverse event profiles (eye pain, irritation). No serious events with either. No head-to-head safety comparison. | Unsupported |
| “"Healed patients don't relapse"” | In the Phase III NK trial, no RGN-259-healed patients had recurrent defects at day 43 (15 days post-treatment). Longer follow-up not published. | Mixed Evidence |
| “"RGN-259 reduces corneal inflammation"” | ARISE-1 and ARISE-2 showed reduced corneal fluorescein staining, consistent with anti-inflammatory effect. Mechanism confirmed in animal models. | Supported |
| “"Thymosin β4 and NGF work through different mechanisms"” | Correct. Tβ4 promotes cell migration via cytoskeletal remodeling. NGF restores neural trophism. Distinct and potentially complementary pathways. | Supported |
| “"RGN-259 prevents corneal melting"” | MMP regulation demonstrated in preclinical models. No human study has tested this specifically. | Preclinical Only |
| “"RGN-259 will be FDA-approved soon"” | No regulatory submission has been publicly announced as of 2025. Phase III data is positive but small (N=18). Timeline unknown. | Unsupported |
| “"RGN-259 works in four weeks"” | Phase III NK trial used a 4-week treatment course with healing assessed at week 4. This is the studied duration. Optimal treatment duration for dry eye is unknown. | Mixed Evidence |
| “"RGN-259 can treat any corneal wound"” | Studies are limited to NK and dry eye. No data on traumatic corneal injuries, chemical burns, or post-surgical healing. Mechanism is plausible but not tested in these settings. | Theoretical |
The Human Evidence Landscape
The human evidence for RGN-259 comes entirely from three clinical trials—all positive, all from the same research group, and all with sample sizes that leave room for statistical uncertainty.
Phase III Neurotrophic Keratopathy (Sosne et al., 2023)
Design: Randomized, placebo-controlled, double-masked Phase III. N: 18 (10 RGN-259, 8 placebo). Intervention: RGN-259 0.1% eye drops, 1 drop four times daily for 4 weeks. Primary findings: Complete corneal healing at 4 weeks: 60% (6/10) RGN-259 vs. 12.5% (1/8) placebo. At day 43: zero recurrences in RGN-259 healed patients; one recurrence in placebo. Limitations: N=18 is small even for a rare disease trial. Single center. The 60% healing rate is based on 6 of 10 patients—adding or removing one patient would substantially change the percentage. No long-term follow-up beyond day 43 published. PMID: 36613994.
ARISE-1 Dry Eye (Sosne et al., 2015)
Design: Randomized Phase II. N: 72 patients with severe dry eye disease. Intervention: RGN-259 0.1%, 1 drop six times daily for 28 days. Primary findings: Significant improvement in corneal fluorescein staining, discomfort scores, and tear breakup time vs. placebo. Limitations: Phase II—not pivotal for registration. 28-day duration for a chronic condition. No long-term follow-up. PMID: 25826322.
ARISE-2 Dry Eye (Sosne et al., 2015)
Design: Randomized Phase II using controlled adverse environment (CAE) model. N: 48 patients. Intervention: RGN-259 0.1%. Primary findings: 27% reduction in discomfort scores vs. placebo (p=0.0244). Significant improvement in central and superior corneal staining. Limitations: CAE model is artificial—real-world environments vary. Smaller N than ARISE-1. PMID: 26056426.
What's Missing
No independent replication—all three studies involve the same investigators and sponsor. No Phase III dry eye data. No long-term follow-up (longest is 43 days). No head-to-head comparison with cenegermin. No pediatric data. No data on corneal healing in non-NK, non-dry-eye populations (chemical burns, post-LASIK, graft rejection). The evidence base is encouraging but narrow.
PLAIN ENGLISH
About 138 total patients have received RGN-259 eye drops across three clinical trials. All three trials showed the drops work—the NK trial was the most dramatic (60% healed vs. 12.5% on placebo). But all three were conducted by the same research team, the largest had only 72 patients, and the longest follow-up was 43 days. No independent group has replicated these findings, and no large-scale pivotal trial has been conducted for dry eye.
Safety, Risks, and Limitations
Known Adverse Effects
RGN-259 has demonstrated a favorable safety profile across all clinical trials: - Eye irritation — mild, transient; the most commonly reported event - No serious ocular adverse events in any trial - No systemic effects — topical ophthalmic delivery with minimal systemic absorption - No immunogenicity concerns reported despite thymosin β4 being a protein
Limitations and Concerns
Small total exposure. Approximately 138 patients have received RGN-259 in clinical trials. This is insufficient to detect adverse events occurring at rates below ~2%.
No long-term safety data. The longest study follow-up is 43 days. For chronic conditions like dry eye, patients would use RGN-259 for months or years. Long-term safety of repeated topical Tβ4 application is unknown.
Potential for pro-tumorigenic effects. Thymosin β4 promotes cell migration and proliferation—properties that are therapeutic in wound healing but theoretically concerning in cancer biology. No evidence of ocular tumor promotion has been observed, and topical concentrations are low, but this theoretical concern exists in the literature for systemic Tβ4 applications.
Regulatory uncertainty. Despite positive Phase III data, the small sample size (N=18) may not satisfy FDA requirements for approval without a confirmatory study.
CRITICAL DISCLAIMER
RGN-259 is investigational and not available outside clinical trials. Thymosin β4 is available from peptide research vendors for systemic use, but these products are not formulated as sterile ophthalmic solutions. Never instill non-pharmaceutical-grade peptide preparations in the eye—the risk of infection, contamination, and corneal damage is serious.
Legal and Regulatory Status
RGN-259 is not FDA-approved for any indication. Phase III data exists for neurotrophic keratopathy; Phase II data exists for dry eye disease. The compound is under development by GtreeBNT (formerly RegeneRx Biopharmaceuticals). No regulatory submission timeline has been publicly announced as of 2025. Cenegermin (Oxervate) is the current FDA-approved treatment for NK and represents the competitive benchmark. WADA does not prohibit thymosin β4. Note: systemic thymosin β4 (TB-500) is available from peptide vendors, but the ophthalmic formulation (RGN-259) is not commercially available.
Research Protocols and Formulation Considerations
Clinical studies used RGN-259 as a 0.1% (1 mg/mL) sterile ophthalmic solution of recombinant thymosin β4. The NK Phase III protocol used four drops daily for four weeks. The dry eye protocols used six drops daily for 28 days. The higher frequency in dry eye reflects the chronic nature of the condition and the shorter contact time on an intact (versus defective) corneal surface.
Thymosin β4 is a 43-amino acid peptide with good aqueous solubility and stability characteristics. Unlike the larger NGF protein, Tβ4's relatively small size and simple structure may facilitate more straightforward manufacturing and formulation—potentially a commercial advantage over cenegermin, which requires frozen storage.
No compounding or self-experimentation community uses ophthalmic thymosin β4. Systemic TB-500 (a synthetic analog) is available from research peptide vendors, but it is not sterile ophthalmic-grade and must never be applied to the eye.
Dosing in Published Research
| Study | Concentration | Frequency | Duration | Route |
|---|---|---|---|---|
| Phase III NK (PMID 36613994) | 0.1% (1 mg/mL) | 4 drops daily | 4 weeks | Topical ophthalmic |
| ARISE-1 Dry Eye (PMID 25826322) | 0.1% (1 mg/mL) | 6 drops daily | 28 days | Topical ophthalmic |
| ARISE-2 Dry Eye (PMID 26056426) | 0.1% (1 mg/mL) | Per protocol (CAE model) | 28 days | Topical ophthalmic |
Note: These are investigational protocols. No approved clinical dosing exists for RGN-259. The difference in frequency between NK (4×/day) and dry eye (6×/day) protocols likely reflects different pharmacodynamic requirements for the two conditions.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into RGN-259 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining RGN-259 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target Tissue | Primary Indication | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Cenegermin | Recombinant human NGF (118 aa homodimer, 0.002% eye drops) | Tier 1 — Approved Drug | Strong Foundation | TrkA/p75NTR → corneal epithelial survival + nerve regeneration | Cornea | Neurotrophic keratitis | Phase III RCTs (N=48 US + N=156 EU); 69.6% vs 29.2% healing | Approved August 2018 (Oxervate) | Not prohibited | 6 drops/day × 8 weeks; frozen storage; high cost; NK indication only |
| Anti-VEGF Peptides | Aptamer (pegaptanib) + antibody fragments (ranibizumab/brolucizumab) + fusion protein (aflibercept) | Tier 1 — Approved Drug | Strong Foundation | VEGF-A neutralization → anti-angiogenesis + anti-permeability | Retina | nAMD; DME; RVO | VISION (N=1,186); MARINA (N=716); VIEW (N=2,419) | Multiple agents approved (2004–2019+) | Not prohibited | Repeated intravitreal injections; endophthalmitis risk; treatment burden |
| RGN-259 | Thymosin β4 (43 aa) 0.1% ophthalmic solution | Tier 2 — Clinical Trials | Reasonable Bet | Actin sequestration → epithelial migration + anti-inflammatory | Cornea | Neurotrophic keratopathy; dry eye | Phase III NK (N=18; 60% vs 12.5%); Phase II dry eye (N=120) | Not approved (Phase III complete) | Not prohibited | Small Phase III N; competing with approved cenegermin; regulatory path pending |
| NGF (Ocular) | Recombinant human NGF (same as cenegermin, broader indications) | Tier 3 — Limited Human Data | Reasonable Bet | TrkA → neuroprotection (RGC) + tear film + epithelial trophism | Cornea; retina | Dry eye; glaucoma neuroprotection; AMD | Phase IIa dry eye (N=40); Phase 1b glaucoma (N=60) | Approved for NK only (Oxervate); not approved for dry eye/glaucoma | Not prohibited | No Phase III for non-NK indications; glaucoma Phase 1b showed trends only |
| SP/IGF-1 Ocular | Tetrapeptide combination (FGLM-NH₂ + SSSR eye drops) | Tier 3 — Limited Human Data | Reasonable Bet | SP/NK-1R priming + IGF-1R adhesion → synergistic epithelial migration | Cornea | Neurotrophic keratopathy (persistent epithelial defects) | Open-label (N=9; 89% healing) | Not approved; no commercial development | Not prohibited | Single research group (Japan); open-label only; no commercial developer |
| Octreotide (Intravitreal) | Cyclic octapeptide SSA (systemic or experimental intravitreal) | Tier 3 — Limited Human Data | Eyes Open | SSTR2/5 → anti-angiogenic + neuroprotective in retina | Retina | Diabetic retinopathy (proliferative) | Small randomized study (N=46; reduced vitreous hemorrhage) | Not approved for retinal use | Not prohibited | Eclipsed by anti-VEGF therapy; no active development program |
| PL-8177 (Ocular) | Selective MC1R agonist (theoretical ocular formulation) | Tier 4 — Preclinical Only | Eyes Open | MC1R → NF-κB suppression → ocular anti-inflammatory | Uvea; conjunctiva | Uveitis; dry eye inflammation (theoretical) | None for ocular use | Not approved; no ocular development | Not prohibited | Entirely theoretical; no ocular formulation or clinical data; IBD is active program |
Frequently Asked Questions
What is the difference between RGN-259 and cenegermin (Oxervate)?
Cenegermin is nerve growth factor (NGF)—it heals the cornea by regrowing the nerves that provide trophic support. RGN-259 is thymosin β4—it heals the cornea by directly telling surface cells to migrate and close the wound. Different molecules, different mechanisms, same clinical goal. Cenegermin is FDA-approved for NK; RGN-259 is not yet approved.
Can I buy thymosin β4 eye drops?
No. RGN-259 is an investigational product available only through clinical trials. Systemic thymosin β4 (TB-500) is sold by peptide research vendors, but these products are not sterile ophthalmic solutions. Never put research-grade peptides in your eyes.
How strong is the Phase III evidence?
The Phase III NK results are statistically and clinically significant—60% healing vs. 12.5% on placebo. The main limitation is the small sample size (18 patients). Whether FDA will require additional data before approval is unclear.
Could RGN-259 and cenegermin be used together?
Theoretically, yes—their mechanisms are complementary (nerve regeneration + cell migration). No study has tested the combination. This could be a compelling clinical strategy for refractory NK.
Is thymosin β4 the same as TB-500?
TB-500 is a synthetic peptide based on the active region of thymosin β4 but is not identical to the full 43-amino acid protein. RGN-259 uses full-length thymosin β4. The two are related but not interchangeable, and TB-500 is not formulated for ocular use.
Why is the Phase III trial so small?
Neurotrophic keratopathy is a rare disease (~5 per 10,000 population). Recruiting patients is difficult. Small trials can be acceptable for rare disease indications under FDA orphan drug and accelerated approval pathways, though regulatory requirements vary.
Does RGN-259 help with dry eye permanently?
Unknown. The Phase II dry eye trials lasted 28 days and showed improvement during treatment. No data exists on whether the effect persists after stopping treatment or whether chronic dosing would be required.
What does \u0022controlled adverse environment\u0022 mean in ARISE-2?
A controlled adverse environment (CAE) chamber is a room with precisely controlled low humidity and high airflow designed to exacerbate dry eye symptoms in a standardized way. It allows researchers to test drug efficacy under consistent conditions rather than relying on variable real-world environments.
Is RGN-259 being tested for other eye diseases?
The current clinical program focuses on NK and dry eye. The thymosin β4 mechanism (cell migration, anti-inflammation, stem cell activation) is theoretically relevant to other corneal conditions, but no additional clinical trials are registered as of 2025.
How does RGN-259 compare to artificial tears?
Artificial tears lubricate the surface but do not promote healing. RGN-259 is pharmacologically active—it triggers biological healing responses (cell migration, inflammation reduction, stem cell activation). They serve different purposes and are not direct competitors.
Could the pro-migration effect of thymosin β4 promote cancer?
Thymosin β4 promotes cell migration, which is theoretically relevant to tumor metastasis. However, no evidence of ocular tumor promotion has been observed with topical RGN-259, and the local concentrations achieved with eye drops are far below systemic levels that might raise concern. This remains a theoretical consideration, not a clinical observation.
When will RGN-259 be available?
No regulatory submission has been publicly announced. Even with positive Phase III data in hand, FDA review typically takes 12–18 months after submission. If a confirmatory study is required, the timeline extends further. The honest answer: we don't know when, or if, RGN-259 will reach the market.
Summary of Key Findings
1. RGN-259 works through a mechanism distinct from cenegermin. Instead of regrowing nerves (NGF pathway), thymosin β4 directly promotes epithelial cell migration, reduces inflammation, and prevents apoptosis. This neural-trophism-independent mechanism makes it relevant to corneal healing regardless of nerve status.
2. Phase III NK data is clinically compelling. A 60% vs. 12.5% complete healing rate is a large, clinically meaningful effect. Zero recurrences in healed patients at day 43 is reassuring. The main caveat is small sample size (N=18).
3. Dry eye data is consistent and encouraging. Two Phase II trials (ARISE-1, ARISE-2) showed significant improvements in both signs and symptoms under different testing conditions. Phase III confirmation is needed.
4. The safety profile is clean but narrowly documented. No serious adverse events across ~138 patients. Mild irritation only. But total exposure is small and follow-up is short.
5. Regulatory and commercial future is uncertain. Despite positive data, no FDA submission has been announced. The competitive landscape includes cenegermin (approved) and the broader anti-inflammatory dry eye market (Restasis, Xiidra). GtreeBNT's ability to navigate this landscape will determine whether RGN-259 reaches patients.
PLAIN ENGLISH
RGN-259 eye drops use a different approach than the approved treatment for corneal nerve disease—instead of regrowing nerves, they directly help surface cells migrate to close the wound. The clinical results are positive: 60% of patients healed in the main trial, and dry eye patients felt and showed improvement. But the studies are small, all from the same research team, and the company hasn't filed for FDA approval yet. It's a real drug candidate with real data, but not a proven treatment.
Verdict Recapitulation
RGN-259 has completed Phase III with positive results—a higher evidentiary bar than most compounds in the peptide space. The thymosin β4 mechanism is distinct, well-characterized, and therapeutically logical. The Phase III NK data (60% vs. 12.5%) and consistent Phase II dry eye data build a credible case for efficacy. Reasonable Bet because the clinical signals are strong but the sample sizes are small, independent replication is absent, and regulatory approval has not been achieved.
For readers considering RGN-259, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source RGN-259
Further Reading and Resources
If you want to go deeper on RGN-259, the evidence landscape for vision & ocular peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Vision & Ocular Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: RGN-259 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sosne, G. et al. (2023). "Thymosin beta 4 ophthalmic solution for neurotrophic keratopathy: results of a randomized, double-masked, placebo-controlled Phase III clinical trial." Eye & Contact Lens, 49(1), 10–15. PMID 36613994
- Sosne, G. et al. (2015). "Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial (ARISE-1)." Clinical Ophthalmology, 9, 877–884. PMID 25826322
- Sosne, G. et al. (2015). "Thymosin β4 eye drops for dry eye in a controlled adverse environment: results of the ARISE-2 clinical trial." Current Eye Research, 40(9), 943–949. PMID 26056426
- Goldstein, A.L. et al. (2005). "Thymosin β4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 11(9), 421–429. [Seminal review of Tβ4 biology]
- Sosne, G. et al. (2016). "Thymosin beta 4 and the eye: a review of the role of thymosin beta 4 in ocular health and disease." International Immunopharmacology, 31, 283–289. PMID 26599493
- Philp, D. et al. (2004). "Thymosin beta 4 promotes corneal wound healing." Investigative Ophthalmology & Visual Science, 45(3), 1072–1078. PMID 14985325
DISCLAIMER
RGN-259 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.